Committee for Advanced Therapies (CAT): 6-8 December 2023, European Medicines Agency, Amsterdam, the Netherlands, from 6 December 2023 to 8 December 2023
Decision of the Management Board amending budget No. 01, amending appropriations in budget 2024
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2024
Maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
Plasmid DNA vaccines for veterinary use – Scientific guideline
Work plan for the Committee for Veterinary Medicinal Products (CVMP) Immunologicals Working Party (IWP) 2024
Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines
Clinical data publication
Summary of opinion: Apexxnar, 25/01/2024 Positive
Orphan designation: 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride Treatment of adrenoleukodystrophy, 18/11/2016 Positive